NEW YORK – Dutch molecular diagnostics firm SkylineDx and the Mayo Clinic have launched a study to evaluate and introduce a new molecular test for primary cutaneous melanoma.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.